



29TH NOV - 3RD DEC 2021



the www.progressiveshares.com

Equities | Derivatives | Commodities | Currency | Depository | Mutual Funds | NBFC | e-Broking



29 Nov 2021 - 03 Dec 2021

DOMESTIC:

- Adani, Tata Power, ReNew to benefit: Solar PLI outlay to be hiked to Rs19,500cr
- Hindujas ready USD1.1bn to up stake in IndusInd Bank
- Jio joins Bharti Airtel and Vodafone Idea, goes for 20% hike in tariffs
- PNB puts up National Steel & Agro Industries Ltd for sale to recover dues
- Monetisation, vendor base expansion key themes of first Paytm earnings call
- Amazon ask CCI to withdraw nod for Reliance-Future deal
- Tata Steel focuses on increasing iron ore production to 45 mtpa in 5 years
- LIC gets RBI nod to raise stake in Kotak bank up to 9.99%
- Amrutanjan enters D2C segment with first offline store
- Freeze on Yes Bank's 25.6% stake in Dish TV spooks private lenders
- RBI supersedes Reliance Capital board, says firm to go for insolvency soon
- Pfizer expects to produce 80mn courses of Covid-19 antiviral pill: Report
- PNB to invest in Open Network for Digital Commerce as promoter
- JMC Projects bags new orders worth Rs1,795cr
- Coal India production rises 4% in November
- Tata Power Solar gets letter of award for Rs945cr project
- Ashoka Buildcon's subsidiary buys 49% stake in Ashoka Highways (Durg)
- UltraTech Cement commences mining from Bicharpur Coal Block
- Serum Institute delivers first Novavax shot through COVAX

ECONOMY:

- Inflation could impede nascent economic recovery
- India leading the world in field of start-ups: PM Modi
- Economists peg India's GDP growth at 7-9% in the second quarter

INDUSTRY:

- Govt aiming for 5G services launch by Aug 15 next year
- RBI-backed digital currency likely to feature in crypto bill: official
- NBFCs eyeing bank tag face a long wait, tighter regulations

Equities | Derivatives | Commodities | Currency | Depository | Mutual Funds | NBFC | e-Brok

PREG

HIGHLIGHTS OF THE WEEK

29 Nov 2021 - 03 Dec 2021

COVERAGE NEWS:

- Sun Pharmaceuticals Ltd: DUSA, wholly owned subsidiary of Sun Pharma has reached a settlement with Biofrontera resolving a litigation. Pursuant to the terms of the settlement, DUSA will receive USD22.5mn from Biofrontera. Additional details regarding the settlement are confidential.
- Zen Technologies Ltd: The company has reported a fire incident at its demonstration center located in Maheshwaram Hardware Park; the facility is insured and the financial damage due to the fire is currently being assessed.
- Gulshan Polyols Ltd: The company has been granted Consent to Establish (CTE) u/s 25 of Water (Prevention & Control of Pollution) Act, 1974 and section 21 of Air (Prevention & Control of Pollution) Act, 1981 for its unit located at industrial growth centre, Goalpara, Assam.
- Supreme Petrochem Ltd: Supreme Petrochem Ltd and Versalis Eni's Chemical Company, technology leader in the chemical industry and one of the largest producers of polymers in Europe, have signed continuous mass ABS technology License and Basic Engineering design agreement for a 70 KTY ABS unit to be built in Amdoshi -Wangani, District Raigad in Maharashtra state (India).

The Week That Went By:

Bears continued to dominate the markets but robust recovery was seen from the lower levels. On 2nd trading session, Index soared higher but the level of 17,280 played a vital role and Index reversed to erase all its gains. In the mid-week, strong momentum was observed across the board where IT and Energy stocks were seen leading the Index. On the last day of the week, Index failed to hold its opening gains and ended the day lower.

Nifty50=17,196.70 BSE Sensex30=57,696.46 Nifty Midcap 100=30,293.25 Nifty Smallcap100=10,827



29 Nov 2021 - 03 Dec 2021

NIFTY (WEEKLY)



BANK NIFTY (WEEKLY)



Nifty50 has almost achieved the target of 16,700 and is now forming a **bullish flag pattern**. **Energy sector** too was seen forming a bullish flag pattern (**Reliance, Tata Power**). **Metal sector** has completed its corrective move of Bullish Cypher pattern and is now about to start its journey towards the north, one should start look into it. (**NMDC**). **Bullish flag** breakout in the **IT sector** is imminent. **PSU Banking sector** has bounced from inverted HNS neckline with a DOJI candlestick pattern, suggesting continuation of an uptrend. **Mid and Small-cap** indices have virtually completed its corrective move and bounced from the lower end of the channel.

▪ PRØG

1 Co

De

29 Nov 2021 - 03 Dec 2021

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)


Your Progress Our Priority... |Currency | Depository | Mutual Funds | NBFC | e-B

Adani Ports	3.05
Asian Paints	-0.73
Axis Bank	1.78
Bajaj Auto	-1.44
Bajaj Finserv	4.50
Bajaj Finance	4.90
Bharti Airtel	-2.40
BPCL	2.28
Britannia	-0.41
Cipla	-5.41
Coal India	2.53
Divis Labs	-3.83
DR Reddy's Labs	-3.26
Eicher Motors	0.62
Grasim	0.96
HCL Tech	5.28
HDFC	1.17
HDFC Bank	1.64

HDFC Life	3.17
Hero Motocorp	-2.45
Hindalco	1.72
HUL	0.32
ICICI Bank	-0.46
Indusind Bank	5.85
INFY	2.84
юс	1.03
ІТС	-0.94
Jsw Steel	2.54
Kotak Bank	-2.04
LT	1.07
M&M	-2.23
Maruti	0.70
Nestle India	0.36
NTPC	-1.28
•	

ONGC	-1.32
PowerGrid	1.63
Reliance	0.33
SBI Life	3.02
SBIN	0.41
Shree Cement	-0.15
Sun Pharma	-1.86
Tata Consumer	0.64
Tata Motors	4.55
Tata Steel	0.40
TCS	5.87
Tech Mahindra	5.26
TITAN	3.64
Ultratech	-0.73
UPL	1.35
Wipro	3.08

SECTORAL PERFORMANCE





29 Nov 2021 - 03 Dec 2021



IT sector ended the week with gains of 3.59%. Frontline stocks i.e. TCS (+5.87%) and HCL Tech (5.28%) were the top gainers followed by Tech Mahindra (+5.26%). As shown in the chart, sector is forming a **bullish flag** pattern; breakout from the same will lead to sharp rally in the sector.



The **Pharma sector** has underperformed Nifty50 by ending the week with a loss of 2.56%. Majority of its components have ended the week with a loss where Glenmark (-5.77%) corrected the most followed by Cipla (-5.41%).

Page No 5



Your Progress Our Priority. addies | Currency | Depository | Mutual Funds | NDFC| e-

29 Nov 2021 - 03 Dec 2021

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

PRØG

as | Darivedives | Comm

• PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

• PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research Analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as pescribed by Securities

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at the discretion of the clients to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd, 122-124, Laxmi Plaza, Laxmi Indl Estate, New Link Rd, Andheri West, Mumbai—400053, Maharashtra www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Mr. Shyam Agrawal, Email: compliance@progressiveshares.com, Contact No.:022-40777500.